Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51.

Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP.

ChemMedChem. 2019 May 17;14(10):1031-1040. doi: 10.1002/cmdc.201900075. Epub 2019 Apr 17.

PMID:
30957434
2.

Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL.

Mol Cancer Ther. 2019 Mar;18(3):507-516. doi: 10.1158/1535-7163.MCT-18-0819. Epub 2019 Jan 23.

PMID:
30674566
3.

Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?

Budke B, Lv W, Kozikowski AP, Connell PP.

ChemMedChem. 2016 Nov 21;11(22):2468-2473. doi: 10.1002/cmdc.201600426. Epub 2016 Oct 26. Review.

4.

Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.

Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP.

J Med Chem. 2016 May 26;59(10):4511-25. doi: 10.1021/acs.jmedchem.5b01762. Epub 2016 Apr 21.

5.

Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration.

Thierry S, Benleulmi MS, Sinzelle L, Thierry E, Calmels C, Chaignepain S, Waffo-Teguo P, Merillon JM, Budke B, Pasquet JM, Litvak S, Ciuffi A, Sung P, Connell P, Hauber I, Hauber J, Andreola ML, Delelis O, Parissi V.

Chem Biol. 2015 Jun 18;22(6):712-23. doi: 10.1016/j.chembiol.2015.04.020. Epub 2015 Jun 4.

6.

RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells.

Mason JM, Dusad K, Wright WD, Grubb J, Budke B, Heyer WD, Connell PP, Weichselbaum RR, Bishop DK.

Nucleic Acids Res. 2015 Mar 31;43(6):3180-96. doi: 10.1093/nar/gkv175. Epub 2015 Mar 12.

7.

The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors.

Mason JM, Logan HL, Budke B, Wu M, Pawlowski M, Weichselbaum RR, Kozikowski AP, Bishop DK, Connell PP.

Cancer Res. 2014 Jul 1;74(13):3546-55. doi: 10.1158/0008-5472.CAN-13-3220. Epub 2014 Apr 21.

8.

DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.

Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP.

Sci Transl Med. 2014 Mar 26;6(229):229ra42. doi: 10.1126/scitranslmed.3008291.

9.

Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing.

Budke B, Chan YL, Bishop DK, Connell PP.

Nucleic Acids Res. 2013 Jul;41(13):e130. doi: 10.1093/nar/gkt362. Epub 2013 May 10.

10.

An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.

Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, Connell PP.

J Med Chem. 2013 Jan 10;56(1):254-63. doi: 10.1021/jm301565b. Epub 2012 Dec 26.

11.

Rad51 is an accessory factor for Dmc1-mediated joint molecule formation during meiosis.

Cloud V, Chan YL, Grubb J, Budke B, Bishop DK.

Science. 2012 Sep 7;337(6099):1222-5. doi: 10.1126/science.1219379.

12.

RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.

Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, Connell PP.

Nucleic Acids Res. 2012 Aug;40(15):7347-57. doi: 10.1093/nar/gks353. Epub 2012 May 9.

13.

Production of clastogenic DNA precursors by the nucleotide metabolism in Escherichia coli.

Budke B, Kuzminov A.

Mol Microbiol. 2010 Jan;75(1):230-45. doi: 10.1111/j.1365-2958.2009.06994.x. Epub 2009 Nov 25.

14.

Hypoxanthine incorporation is nonmutagenic in Escherichia coli.

Budke B, Kuzminov A.

J Bacteriol. 2006 Sep;188(18):6553-60.

Supplemental Content

Support Center